Copyright Reports & Markets. All rights reserved.

Global Nanomaterial-Based Adjuvants Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Aluminium Hydroxides
    • 1.3.3 Aluminium Phosphate
    • 1.3.4 Lipidosome
    • 1.3.5 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Pneumococcus
    • 1.4.3 Human Papilloma Virus
    • 1.4.4 DTaP
    • 1.4.5 Viral Hepatitis TypeA
    • 1.4.6 Viral Hepatitis TypeB
    • 1.4.7 SARS-CoV-2
    • 1.4.8 Others
  • 1.5 Global Nanomaterial-Based Adjuvants Vaccine Market Size & Forecast
    • 1.5.1 Global Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019 & 2023 & 2030)
    • 1.5.2 Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity (2019-2030)
    • 1.5.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price (2019-2030)

2 Manufacturers Profiles

  • 2.1 Emergent BioSolutions
    • 2.1.1 Emergent BioSolutions Details
    • 2.1.2 Emergent BioSolutions Major Business
    • 2.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product and Services
    • 2.1.4 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Emergent BioSolutions Recent Developments/Updates
  • 2.2 Sanofi
    • 2.2.1 Sanofi Details
    • 2.2.2 Sanofi Major Business
    • 2.2.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Product and Services
    • 2.2.4 Sanofi Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Sanofi Recent Developments/Updates
  • 2.3 GlaxoSmithKline Biologicals
    • 2.3.1 GlaxoSmithKline Biologicals Details
    • 2.3.2 GlaxoSmithKline Biologicals Major Business
    • 2.3.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product and Services
    • 2.3.4 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 GlaxoSmithKline Biologicals Recent Developments/Updates
  • 2.4 Merck
    • 2.4.1 Merck Details
    • 2.4.2 Merck Major Business
    • 2.4.3 Merck Nanomaterial-Based Adjuvants Vaccine Product and Services
    • 2.4.4 Merck Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Merck Recent Developments/Updates
  • 2.5 Pfizer
    • 2.5.1 Pfizer Details
    • 2.5.2 Pfizer Major Business
    • 2.5.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Product and Services
    • 2.5.4 Pfizer Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Pfizer Recent Developments/Updates
  • 2.6 Novartis
    • 2.6.1 Novartis Details
    • 2.6.2 Novartis Major Business
    • 2.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Product and Services
    • 2.6.4 Novartis Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Novartis Recent Developments/Updates
  • 2.7 Moderna
    • 2.7.1 Moderna Details
    • 2.7.2 Moderna Major Business
    • 2.7.3 Moderna Nanomaterial-Based Adjuvants Vaccine Product and Services
    • 2.7.4 Moderna Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Moderna Recent Developments/Updates

3 Competitive Environment: Nanomaterial-Based Adjuvants Vaccine by Manufacturer

  • 3.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Manufacturer (2019-2024)
  • 3.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Manufacturer (2019-2024)
  • 3.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Manufacturer (2019-2024)
  • 3.4 Market Share Analysis (2023)
    • 3.4.1 Producer Shipments of Nanomaterial-Based Adjuvants Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2023
    • 3.4.2 Top 3 Nanomaterial-Based Adjuvants Vaccine Manufacturer Market Share in 2023
    • 3.4.3 Top 6 Nanomaterial-Based Adjuvants Vaccine Manufacturer Market Share in 2023
  • 3.5 Nanomaterial-Based Adjuvants Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Nanomaterial-Based Adjuvants Vaccine Market: Region Footprint
    • 3.5.2 Nanomaterial-Based Adjuvants Vaccine Market: Company Product Type Footprint
    • 3.5.3 Nanomaterial-Based Adjuvants Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region
    • 4.1.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Region (2019-2030)
    • 4.1.2 Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Region (2019-2030)
    • 4.1.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Region (2019-2030)
  • 4.2 North America Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030)
  • 4.3 Europe Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030)
  • 4.4 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030)
  • 4.5 South America Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030)
  • 4.6 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030)

5 Market Segment by Type

  • 5.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
  • 5.2 Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Type (2019-2030)
  • 5.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Type (2019-2030)

6 Market Segment by Application

  • 6.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
  • 6.2 Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Application (2019-2030)
  • 6.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Application (2019-2030)

7 North America

  • 7.1 North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
  • 7.2 North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
  • 7.3 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Country
    • 7.3.1 North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2030)
    • 7.3.2 North America Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2030)
    • 7.3.3 United States Market Size and Forecast (2019-2030)
    • 7.3.4 Canada Market Size and Forecast (2019-2030)
    • 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe

  • 8.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
  • 8.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
  • 8.3 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Country
    • 8.3.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2030)
    • 8.3.2 Europe Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2030)
    • 8.3.3 Germany Market Size and Forecast (2019-2030)
    • 8.3.4 France Market Size and Forecast (2019-2030)
    • 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
    • 8.3.6 Russia Market Size and Forecast (2019-2030)
    • 8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific

  • 9.1 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
  • 9.2 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
  • 9.3 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Region (2019-2030)
    • 9.3.2 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Consumption Value by Region (2019-2030)
    • 9.3.3 China Market Size and Forecast (2019-2030)
    • 9.3.4 Japan Market Size and Forecast (2019-2030)
    • 9.3.5 South Korea Market Size and Forecast (2019-2030)
    • 9.3.6 India Market Size and Forecast (2019-2030)
    • 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
    • 9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America

  • 10.1 South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
  • 10.2 South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
  • 10.3 South America Nanomaterial-Based Adjuvants Vaccine Market Size by Country
    • 10.3.1 South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2030)
    • 10.3.2 South America Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2030)
    • 10.3.3 Brazil Market Size and Forecast (2019-2030)
    • 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa

  • 11.1 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
  • 11.2 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
  • 11.3 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2030)
    • 11.3.2 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2030)
    • 11.3.3 Turkey Market Size and Forecast (2019-2030)
    • 11.3.4 Egypt Market Size and Forecast (2019-2030)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
    • 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics

  • 12.1 Nanomaterial-Based Adjuvants Vaccine Market Drivers
  • 12.2 Nanomaterial-Based Adjuvants Vaccine Market Restraints
  • 12.3 Nanomaterial-Based Adjuvants Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Nanomaterial-Based Adjuvants Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Nanomaterial-Based Adjuvants Vaccine
  • 13.3 Nanomaterial-Based Adjuvants Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Nanomaterial-Based Adjuvants Vaccine Typical Distributors
  • 14.3 Nanomaterial-Based Adjuvants Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Nanomaterial-Based Adjuvants Vaccine market size was valued at US$ 26520 million in 2023 and is forecast to a readjusted size of USD 44640 million by 2030 with a CAGR of 7.8% during review period.
    Global key players of Nanomaterial-Based Adjuvants Vaccine include Emergent BioSolutions, Sanofi, etc. Global top 3 companies hold a share over 80%. North America is the largest market, with a share about 60%, followed by Europe and Japan with the share about 20% and 5%. In terms of product, Lipidosome is the largest segment, with a share about 80%. And in terms of application, the largest application is SARS-CoV-2, with a share about 75%.
    This report is a detailed and comprehensive analysis for global Nanomaterial-Based Adjuvants Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
    Key Features:
    Global Nanomaterial-Based Adjuvants Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2019-2030
    Global Nanomaterial-Based Adjuvants Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2019-2030
    Global Nanomaterial-Based Adjuvants Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2019-2030
    Global Nanomaterial-Based Adjuvants Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (M Doses), and ASP (US$/Dose), 2019-2024
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Nanomaterial-Based Adjuvants Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Nanomaterial-Based Adjuvants Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis, Moderna, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Nanomaterial-Based Adjuvants Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Aluminium Hydroxides
    Aluminium Phosphate
    Lipidosome
    Others
    Market segment by Application
    Pneumococcus
    Human Papilloma Virus
    DTaP
    Viral Hepatitis TypeA
    Viral Hepatitis TypeB
    SARS-CoV-2
    Others
    Major players covered
    Emergent BioSolutions
    Sanofi
    GlaxoSmithKline Biologicals
    Merck
    Pfizer
    Novartis
    Moderna
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Nanomaterial-Based Adjuvants Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Nanomaterial-Based Adjuvants Vaccine, with price, sales quantity, revenue, and global market share of Nanomaterial-Based Adjuvants Vaccine from 2019 to 2024.
    Chapter 3, the Nanomaterial-Based Adjuvants Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Nanomaterial-Based Adjuvants Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Nanomaterial-Based Adjuvants Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Nanomaterial-Based Adjuvants Vaccine.
    Chapter 14 and 15, to describe Nanomaterial-Based Adjuvants Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now